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Background: Cyclosporine is an immunosuppressive agent used to treat immune-mediated and
inflammatory diseases in dogs. We have developed a pharmacodynamic (PD) assay that measures
interleukin-2 (IL-2) produced by activated T cells to measure the immunosuppressive effects of
cyclosporine.
Hypothesis/objectives: Our retrospective study extracted data from samples submitted to our
laboratory to obtain descriptive statistics, to determine whether assay results predicted treatment
effectiveness, and to determine whether cyclosporine formulation or breed affected PD responses.
Animals: 1,110 samples were analyzed over 4 years.
Methods: Extracted data was analyzed to determine whether there was a relationship between
assay results and clinical control, and whether either formulation or breed affected results.
Results: We found no relationship between assay results and control of signs, and found that breed
did not affect results. At comparable doses, proprietary modified cyclosporine was more
immunosuppressive than proprietary non-modified cyclosporine, and both proprietary and generic
modified formulations had similar efficacy.
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CHAPTER I
INTRODUCTION
Origin
Cyclosporine is a xenobiotic, originating from polypeptide macrolides that were first
isolated from a fungus called Tolypocladium inflatum. Cyclosporine was first developed into
cyclosporine A in 1972 by a company called Sandoz 1. Even though cyclosporine has been used
therapeutically for many years, there are many drug characteristics that are still not well
understood, particularly in dogs. As one example, while it is known that cyclosporine is
metabolized by the cytochrome P450 (CYP) enzyme in dogs, the CYP subset responsible for this
metabolism in dogs is not fully know.
Uses
In humans, cyclosporine has mainly been used to prevent organ transplant rejection 2. In
veterinary medicine, cyclosporine is more versatile, and it has been used not only for organ
transplantation (particularly in cats) 34 but also for immune-mediated diseases, such immunemediated hemolytic anemia (IMHA) and immune-mediated thrombocytopenia (IMTP) 5 6, for
inflammatory skin diseases 7, for inflammatory bowel disease (IBD) 8 and for chronic ulcerative
periodontal stomatitis (CUPS) 8.
An ideal agreement upon starting cyclosporine dosage in dogs has not been identified, in
part because each individual is different, and because each disease will behave differently in
each patient 10. Attaining or exceeding desired immunosuppressive effects, when using
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cyclosporine doses recommended for the treatment of immune-mediated and inflammatory
diseases, may also predispose to opportunistic infection 11. The most common manifestation of
secondary infections in dogs is cutaneous infection, typically seen with prolonged drug use 11.
Mechanism of Action and Metabolic Pathways
The main mechanism of action of cyclosporine is inhibition of T cell expression of
interleukin-2 (IL-2) and other cytokines via blockage of the conjugation of a calcium ion to the
enzyme calcineurin, that will be inhibited by cyclophilin/cyclosporine complex (a peptidylprolyl
isomerase A complex that is found in the cytoplasm) 12. Resultant calcineurin inhibition prevents
the dephosphorylation of nuclear factor of activated T-cells (NFAT), thereby preventing
movement of NFAT into the nucleus, and ultimately preventing the production of NFATregulated cytokines such as IL-2 13.
Orally administered cyclosporine will be absorbed from the intestinal tract by the
enterocytes, and then some active cyclosporine will be pushed back to the intestine lumen by
enterocyte efflux pumps, where the drug might then be absorbed by another enterocyte, or
eventually secreted in the feces. Some of the active cyclosporine within enterocytes will be
metabolized by CYPs inside the cell, with a mix of active and inactive metabolites then secreted
into either the intestinal lumen or portal circulation 14. Some active cyclosporine will be moved
from the enterocytes to the hepatoportal vessels, where it will be delivered to the liver and
absorbed by hepatocytes. Some cyclosporine will again be pumped out of the hepatocytes by
efflux pumps into the biliary system, where it will again eventually re-enter the gut lumen and be
re-absorbed by enterocytes or secreted in the feces. Some active cyclosporine in the hepatocyte
will be also metabolized by CYPs, and cyclosporine and its active and inactive metabolites will
eventually enter the systemic circulation and reach the target cell, the T cell 15 16
2

Bioavailability
Oral bioavailability of cyclosporine is notoriously highly variable, often based on factors
such as which formulation of cyclosporine is used, intestinal motility, enterocyte CYP and efflux
pump activity, and bile flow 17. The bioavailability of cyclosporine will change depending on
how the drug is formulated: if it a lipid formulation like Sandimmune®, the bioavailability will
be from 20 to 27%, whereas the bioavailability of the micro-emulsified (or modified)
formulation (Neoral®, Atopica®) is about 35% 15. Oral bioavailability, however, may decrease if
the intestinal tract is stimulated by concurrent feeding 18
Therapeutic Drug Monitoring
Since the bioavailability of cyclosporine is unpredictable, a perfect single oral dose that is
suitable for every dog does not exist. Furthermore, if the dose is too low there will not be
adequate control of the treated disease, and if the dose is too high the chances of side effects will
be increased. There is therefore a need for close monitoring of therapy in order to optimize
treatment. Rejection of transplanted organs is one major concern associated with cyclosporine
use in human medicine, and therapeutic drug monitoring (TDM) is therefore typically used to
ensure adequate immunosuppression and minimize organ rejection. Therapeutic drug monitoring
can either involve pharmacokinetic (PK) monitoring (the study of absorption, metabolization and
excretion of a drug or, more simply, “what the body does to a drug”) 19, or pharmacodynamic
(PD) monitoring (studies that evaluate the reaction between a drug and an organism, or “what a
drug does to the body”) 20. In human transplant medicine, PD monitoring of biomarkers of
immune suppression has been shown to be more efficient at preventing rejection and reducing
drug side effects than PK monitoring 16. Pharmacodynamic monitoring of biomarkers of T cell
suppression includes monitoring of NFAT-regulated cytokines such as IL-2 and interferon
3

gamma (IFN-y), as well as measurement of NFAT and calcineurin activity 16 9. In human
medicine, it is recognized that there still room for improvement for both PK and PD models of
cyclosporine TDM 16. Even though TDM for both PK and PD has evolved in small animal
medicine1, there is still room for improvement for PK and PD models 16.
Side Effects
Cyclosporine reduces T-cell function, thus inhibiting immune system responses and
potentially opening the door to opportunistic infections. For example, in dogs there have been
reports of cutaneous infections with unusual fungal organisms after prolonged cyclosporine
treatment 11, and in cats cyclosporine use has been associated with the development of systemic
toxoplasmosis 21. T cells also play an essential role in protection against viral infections, and
reduced T-cell function associated with cyclosporine use can allow for multiplication of viruses
like papilloma virus 22.
T-cells play an essential role in fighting neoplasia. The extensive use of cyclosporine can
predispose to cancer by reducing proliferation and function of natural killers (NK) cells. With
NK inhibition, abnormal cells can replicate easily, rather than being destroyed by the immune
system, and this will allow the potential formation of neoplasia.23.
Pharmacodynamic Laboratory
Observing the patient closely while using cyclosporine during long term therapy is
recommended, because diagnosing secondary infections as soon as possible makes it easier to
treat these infections, and to adjust the cyclosporine dose as needed 24. With the addition of PD
therapeutic drug monitoring, we can also evaluate the effects of cyclosporine on patient T cells,
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which allows us to control cyclosporine dose rates in order to avoid over-immunosuppression,
thereby potentially avoiding the development of secondary infections in the first place. 9.
Although we have been using cyclosporine in dogs for several decades, we still have
much more to learn about the appropriate use of the drug. Here at the Mississippi State
University Pharmacodynamic Laboratory, we have developed an assay that measures the amount
of IL-2 produced by activated T cells. This assay allows us to directly assess the effects of
cyclosporine on T cells, and to use this information to adjust cyclosporine doses. For the past
five years, the Pharmacodynamic Laboratory has analyzed more than 1000 samples submitted by
veterinarians from dogs receiving cyclosporine, giving us the opportunity to dissect data from
these cases, and to look more closely at multiple TDM-related factors, ranging from the effect of
dog breed on results to the relationship between results and any cyclosporine-related side effects.
Analysis of collected data allows us to take a closer look at individual dog breeds, and to search
for breed effects that may suggest genetic variations that may explain why this drug at standard
doses appears to be more effective, or better tolerated, in some dogs but not in others. Currently,
we are still unsure if there are breed differences regarding efficacy and tolerance of cyclosporine.
Another question that can potentially be answered by data analysis is whether there is a variation
in efficacy of T-cell inhibition between dogs that are receiving proprietary (brand name) microemulsified (modified) cyclosporine, the most expensive drug formulation, compared to dogs that
are receiving any of the other available versions of the drug, such as generic, compounded, or
non-modified cyclosporine. Finally, one vital question that has not been answered in dogs is
whether the pharmacodynamic assay that is currently being utilized to monitor cyclosporine
therapy actually predicts correct dosing and clinical control of disease.

5

All the questions above, and more, need to be answered to improve efficacy of
cyclosporine use in dogs. This dissertation is a retrospective study where we aim to
comprehensively search the collected data from all pharmacodynamic assays of activated T-cell
IL-2 production of dogs performed through the Mississippi State University College of
Veterinary Medicine Pharmacodynamic Laboratory, in order to look for patterns that may allow
us to more thoroughly explain how cyclosporine works in the canine patient. We hope that this
analysis will provide answers to some important and currently unanswered questions regarding
cyclosporine use in dogs.
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CHAPTER II
LITERATURE REVIEW
Background
The discovery of a group of polypeptide macrolides in 1971 and later on, in 1972, their
manipulation into cyclosporine by a company called Sandoz started a new era in
immunopharmacology 1. These polypeptides were first isolated from a fungus called
Tolypocladium inflatum 1 in 1970 from two soil samples, one from Wisconsin, USA and the
second from Hardanger Vidda, Norway. Cyclosporine was the first immunosuppressive drug
discovered that facilitated the selective inhibition of T cells without unacceptable toxicity.
Cyclosporine’s immunosuppressive properties were characterized by J.F Borel in 1983 2. At that
time, efforts to prevent organ transplant rejection had mostly been focused on the concurrent use
of azathioprine and corticosteroids, however the long-term use of both drugs was associated with
limited efficacy and severe side effects, including bone marrow depression and hepatic toxicity
34

. Cyclosporine, with its greater efficacy and more desirable side effect profile, revolutionized

human transplant medicine.
Cyclosporine has been now studied and used in both humans and dogs for several
decades, and today we know much more about the drug than twenty years ago, although even
after so many years of use there are still many aspects of cyclosporine that are still not well
understood. For example, the cytochrome P450 (CYP) sub-set that is responsible for
cyclosporine metabolism in dogs is not known with certainty, nor is the most effective dosing
4

strategy to establish acceptable levels of immune suppression without toxicity. Based on our
experience with this drug, it appears that each individual patient has the potential to have a
different response to cyclosporine 5
Mechanism of action
Immunosuppression
When the immune system is stimulated in an individual that is not being treated with
cyclosporine, T cells will receive an external stimulus, allowing calcium ions to penetrate
through the cell wall. The calcium ion will bind to calmodulin (a calcium receptor present inside
T cells) 6, where it will be presented to the enzyme calcineurin (a protein phosphatase 3 7).
Nuclear factor of activated T cells (NFAT) will be activated by calcineurin via
dephosphorylation, and NFAT will then migrate into the nucleus where it will stimulate the
upregulation of a number of different cytokines involved in the immune system, such as of
interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL13), tumor
necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) 8. Secretion of cytokines such as
IL-2 during this process will incite other T cells to multiply 9.
Cyclosporine acts as a calcineurin inhibitor: it prevents activation of calcineurin, thereby
not allowing dephosphorization of NFAT, and thus not permitting upregulation of the NFATregulated cytokines such as IL-2 10. Inside the cell, cyclosporine binds to cyclophilin A, an
abundant cytosolic protein that serves to hold cyclosporine within the cell. The cyclophilins are
immunophilins that will bind to drugs like cyclosporine and to the FK506 protein of tacrolimus,
another calcineurin inhibitor, and are found in T cells, enterocytes, and other cells 11. In fact, it is
actually the cyclosporin-cyclophilin A complex that most effectively inhibits calcineurin.
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Cyclosporine is a potent inhibitor of T-cell function and multiplication, and the associated
immunosuppression is used to control immune-mediated diseases as immune-mediated
hemolytic anemia 12, immune-mediated thrombocytopenia and immune-mediated
polyarthritis 10 13.
Anti-inflammatory effects
T cells play an important role in inflammation, including release of pro-inflammatory
cytokines such as interleukins and TNF-α 14. Cyclosporine-associated T-cell suppression can
therefore be used to reduce inflammation. Cyclosporine is used to treat a number of
inflammatory diseases, including inflammatory bowel disease 15. Beyond the suppressive effects
on T cells, cyclosporine also has anti-inflammatory effects on other white blood cells, such as
macrophages, eosinophils, and basophils. These effects may be mediated by inhibition of nitrite
accumulation, either directly or by inhibition of thromboxane in mesangial cells, or by the
accumulation of COX-2 mediated PGE2 14 16. Since cyclosporine has the ability to downregulate
production of pro-allergenic cytokines, the drug is also used to treat allergic reactions 17.
Organ allograft effects
The use of cyclosporine to prevent organ rejection in veterinary medicine has been
documented with renal transplantation, particularly in cats, where cyclosporine is used
concurrently with steroids, especially prednisolone 18. Life expectancy after renal transplantation
in cats is about 18 months, but the concurrent use of prednisolone and cyclosporine can increase
life expectancy significantly 19. In 2008, a retrospective study was published showing that 77.5%
of feline patients with renal allografts were discharged from the hospital and survived
approximately 2 years. A significant number of these patients (37%), however, developed
6

secondary infections 20. In human transplant, it has long been recognized that, despite relatively
high success rates, improvement in rates of both transplant rejection and rejection could still be
achieved by refinement of both pharmacodynamic (PD) and pharmacokinetic (PK) assays during
cyclosporine therapy. 4
Pharmacodynamics & Pharmacokinetics
Formulation
The first formulation of cyclosporine, the proprietary version of which was called
Sandimmune®, was created in an oil/alcohol base, available as soft gelatin capsules for oral
administration, and as an intravenous solution 21. The intravenous solution had a
polyoxymethylene castor oil vehicle that has been associated with anaphylaxis 2223. The company
Novartis then created a new modified microemulsion of cyclosporine in 1995, with the
commercial name of Neoral®, which had surfactant, lipophilic and hydrophilic solvents, plus
ethanol 24. This allowed a higher blood bioavailability of cyclosporine at lower oral doses, and
also appeared to reduce adverse drug effects 2425. Later, Atopica® was approved for veterinary
use, which was also a microemulsified cyclosporine formulation comparable to Neoral®. For all
of the various proprietary formulations of cyclosporine, there are now also comparable generic
versions available. Nowadays, easy access to the cyclosporine active metabolite has made it
relatively easy for independent pharmacies to manipulate the drug and make a compounded
version of the drug, thereby making compounded cyclosporine attractive as a more affordable
and easier dosing option for veterinarians. The efficacy of compounded cyclosporine, however,
has not been established.
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Absorption
Once cyclosporine is ingested, it will be absorbed by enterocytes in the intestines, where
part of it will be pushed out of the cell by the enterocyte efflux pump P-glycoprotein back to the
lumen of the intestine, where it can be absorbed again by another enterocyte, or excreted in the
feces. Another portion of cyclosporine within the enterocyte will be metabolized by enterocyte
CYP enzymes into a range of variably active metabolites. Some intact cyclosporine from within
enterocytes, plus cyclosporine metabolites, will eventually enter the portal circulation, where
they will be delivered to the liver. Once at the liver, cyclosporine and its metabolites will be
absorbed by hepatocytes, where hepatic efflux pumps can pump the drug and its metabolites into
the biliary system, where eventually they enter the intestinal lumen and are re-introduced to
enterocytes, and also are excreted in the feces. Intact cyclosporine will also be further
metabolized by CYP enzymes present in the hepatocytes, before some intrahepatocyte
cyclosporine and its metabolites eventually will enter the systemic blood stream.
Oral bioavailability of cyclosporine can be affected by several important factors. First,
bioavailability is significantly influenced by the formulation of the drug, namely whether it is a
lipid formulation (Sandimmune® or comparable generics) or microemulsified or “modified”
(Neoral®, Atopica®, or comparable generics). The Sandimmune® type formulation will have
significantly less oral bioavailability, at about 20% to 27% in humans, when compared to the
modified formulation, where bioavailability is around 35% (Steffan et al., 2004) (Mehl et al.,
2003). A second factor that will change the bioavailability of cyclosporine is bile flow. Because
of the lipophilic behavior of cyclosporine, it depends on bile salts to be absorbed in the intestine,
and thus when bile flow is high and the concentrations of bile salts in the intestine are also high,
there is an increase in cyclosporine absorption 26. Bile flow will vary depending on whether the
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patient has just had food or not (Colombo & Egan, 2010). Even though the manufacture
recommends that modified cyclosporine should be given at least one hour before or two hours
after food for dogs (Novartis inc, n.d.), in cats it is recommended that cyclosporine be
administered with food to allow higher bioavailability (Elanco US Inc, n.d.). Peak drug
concentration will be reached between 1 and 2 hours after the oral administration of cyclosporine
(Guaguère et al., 2004) and the trough concentration is noted between 6 and 12 hours after
administration of cyclosporine. (Claire L. Fellman, 2016). Oral cyclosporine bioavailability can
also be influenced by factors that affect CYP enzyme activity and P-glycoprotein efflux pump
activity, such as treatment with ketoconazole 27 or cimetidine 28 as well as many other drugs, and
inherited mutations in the multidrug resistance gene (MDR-1) 29.
Distribution
Cyclosporine is a lipophilic substance, hence it is widely distributed across peripheral
tissues, where its volume of distribution may vary from 3 to 5 L/kg 21 23. There may be different
concentrations of cyclosporine within different components of the blood: for example,
cyclosporine concentration may vary from 33% to 47% within the plasma. These high
concentrations are due to the large number of lipoproteins present in the plasma that can bind to
cyclosporine 30. Cyclosporine can also bind to albumin within the plasma. Unbound cyclosporine
is typically the form of the drug that is metabolized by CYPs and that is excreted, as mentioned
before, directly into to the intestine lumen, or via the bile ducts 21. In dogs, cyclosporine peak
concentrations are achieved from 1 to 2 hours of oral administration, while trough concentrations
can be anywhere beyond 6-12 hours of administration 31.
In a human study in 1991 (Lensmeyer et. al.), within the tissues of patients that were on
cyclosporine for organ transplantation, the tissues that had the highest concentration of active
9

cyclosporine were the pancreas, then the spleen, liver, fat, kidneys, lung, bone marrow, heart
muscle and whole blood. The same study showed that the cyclosporine in fat tissue was mostly
unmetabolized.
Cyclosporine at relatively low doses is used to control skin diseases, and is particularly
effective because drug concentrations in the skin tissues can be 2 to 6 times greater than blood
concentrations 27. High skin drug concentrations appear to occur because of the slow elimination
of cyclosporine from the skin tissues 3233.
Metabolism
In humans, it is known that cyclosporine is metabolized by the cytochrome P450
subfamily CYP3A, primarily within hepatocytes, although some metabolization will occur in
enterocytes and renal cells. 30. Cyclosporine metabolism can be influenced by different
medications when used concurrently with cyclosporine, particularly drugs that either inhibit or
promote CYP enzyme or P-glycoprotein pump activity (Table A.1, A.2). 35 Ketoconazole, for
example, can markedly enhance the bioavailability of cyclosporine by inhibiting CYP enzyme
function and delaying metabolism of the drug.27.
In humans, when cyclosporine is metabolized by CYP enzymes in the liver, the main
process of metabolization via the CYP3A4 subfamily is through N-demethylation and
hydroxylation, where N-demethylation produces the M-21 cyclosporine metabolite, and
hydrolyzation produces the M-1 and M17 metabolites 35.
In cats and dogs, it is still not known with certainty what specific subfamily of CYP
enzymes metabolizes cyclosporine. In cats, there have been studies evaluating that the CYP
subfamily that is mainly responsible for the metabolization of cyclosporine 36 37. One study
demonstrated that there was a different drug metabolization process in male cats compared to
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female cats. Male cats had more CYP2D present, while females had more CYP3A, similar to
humans 36. In dogs, there have been studies showing that CYP3A12 is the main CYP subfamily
that is inhibited by ketoconazole 38 39. Since administration of ketoconazole has been shown to
increase cyclosporine blood levels in dogs, this suggests that CYP3A12 may be the CYP enzyme
that metabolizes cyclosporine 40 The relationship between ketoconazole and cyclosporine allows
veterinarians to administer ketoconazole to reduce the dose of cyclosporine used and achieve the
same drug effects (Alison J. Patricelli et al., 2002) (A. D’mello et al., 1989) 43, thereby reducing
the cost of treatment 40.
Excretion
The elimination half-life of cyclosporine in dogs is about eight hours, and most of its
metabolites when biotransformed in enterocytes and hepatocytes are then secreted either directly
into the intestine lumen, or into the bile canaliculi 44. Along with its metabolites, about 1% of the
active cyclosporine is also excreted by similar pathways

45

. Renal excretion of cyclosporine may

also occur in dogs; however, the amount of cyclosporine and it’s metabolites that are excreted in
the urine is minimal 4632.
Adverse Effects
Nephrotoxicity is one of the most common adverse effects reported while using
cyclosporine for long periods of time in humans. There have been reports of both acute and
chronic renal damage with cyclosporine therapy in humans following renal transplantation, and
this issue can contribute to the failure of renal allografts 47104849. There have been various theories
on the mechanism of nephrotoxicity, including excessive activation of the renin-angiotensinaldosterone cascade, which will increase endothelin-1, and down regulation of the sympathetic
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system, causing an increase in transformation growth factor beta (TGB- β), leading to renal
fibrosis.501051.
In veterinary medicine, nephrotoxicity does not appear to be a significant concern at
standard doses. In a study with 34 dogs with renal transplants (R. Y. Calne et al., 1979) using an
extremely high cyclosporine dosage of 50 mg/kg per day, 4% of the patients had hepatic
necrosis, 35% died of infection and 23% had organ rejection, although it may potentially be
difficult to distinguish allograft-associated kidney rejection or other renal diseases from druginduced nephrotoxicity. Secondary infections, however, were reported as the most common
cause of organ rejection post-surgery. According to the Atopica® drug insert, the most common
side effects with prolonged use of cyclosporine in dogs are emesis and diarrhea, when using a
dose of 5 mg/kg once a day. Nuttal and others reported that, although about 55% of dogs
receiving cyclosporine demonstrate adverse effects, side effects were only severe enough to
necessitate discontinuation of the drug in 4% of those dogs. The most common side effects were
gastrointestinal (46%), and other less frequent events included gingival hyperplasia (1%),
papillomatosis, hirsutism, and secondary infections 50. Cyclosporine has been found to be
associated with insulin resistance in some cases 53.
The use of cyclosporine has been associated with tumorous growth, however it is
proposed that cyclosporine does not cause tumor growth directly, but rather that cyclosporineassociated suppression of the immune system that can favor the growth of malignant cells. 54
Pharmacokinetics
The term “pharmacokinetics” generally refers to the handling of a drug by the body, with
a focus on drug absorption, distribution, metabolism, and elimination. A knowledge of these
processes is essential to understand how a drug behaves in the body 55. Pharmacokinetic (PK)
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modeling is typically centered on the measurement of drug concentrations, particularly in the
blood.
The first technique routinely developed for cyclosporine blood quantification was high
performance liquid chromatography (HPLC), and HPLC is still considered to be the gold
standard method even though it is time consuming and complex to perform. HPLC made it
possible to identify both the cyclosporine active compound and its metabolites 56 57. Later other
polyclonal assays (immunoassays), such as radioimmunoassay and fluorescence polarization
immunoassays were developed, and were much easier to perform and less time consuming.
These new assays allowed the scientific community to see what metabolite is released where and
at what concentration 58. The ideal sample on which to perform cyclosporine assays has been a
subject of controversy when measuring cyclosporine blood concentrations, and there have been
arguments that plasma was better than whole blood and vice-versa. Early studies showed that
levels of cyclosporine in plasma may vary depending on temperature, with lower concentrations
at lower sample temperatures 59. It has been recommended that plasma samples be held for 30
minutes at 37oC in order to attain stable cyclosporine blood levels 60. Another factor that will
affect measured cyclosporine blood concentrations is the patient’s hematocrit since the drug is
almost evenly distributed between plasma (33-47%) and blood (41-58%). The use of whole
blood rather than serum for the analysis of cyclosporine blood levels has become more common,
due to the fact that cyclosporine is sequestered within red blood cells (RBC), in addition to being
bount to lipoproteins present in the plasma 61. The use of whole blood also helps standardize the
process of monitoring across different assays 62. In target lymphocytes, the surface membrane Pglycoprotein efflux pump will remove cyclosporine from the cell and secrete the drug back into
the extracellular space, altering drug concentrations inside the cell 63
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Measurement of blood cyclosporine peak and/or trough blood concentrations has been
routinely used for therapeutic drug monitoring (TDM) to predict drug effects in both human and
veterinary patients receiving cyclosporine. Trough blood concentrations of cyclosporine may be
a less accurate method for measuring drug effects, since the timing of the trough sample and
resultant drug concentrations will vary depending on how often cyclosporine is administered. In
humans, peak cyclosporine concentrations may provide better estimates of drug effects, perhaps
in part because peaks tend to occur over a predictably narrow period, anywhere between 1 and 2
hours after oral administration 64 65. One limitation of using peak blood concentrations for TDM
is that cyclosporine can achieve extremely high blood concentrations, sometimes requiring
dilution steps for analysis 65 66. In dogs, the standard recommendation for timing of measurement
of cyclosporine blood concentrations is still to utilize predominantly trough blood levels. 6768.
Different recommended target whole blood trough concentrations in dogs exist, and can include
300-500 or 400-700ng/dl depending on the source 69 66. Target concentrations will, however,
vary with disease: the initial recommended whole blood concentration for treating inflammatory
diseases is between 400-600 ng/mL, but for anal furunculosis the minimum recommended target
blood cyclosporine concentration is at least 200 ng/mL 41.
Measurement of blood cyclosporine concentrations for TDM during organ transplantation
in humans is still considered to be essential due to marked individual variability of
bioavailability and drug metabolism. Measurement of blood concentrations alone, however, can
be an issue, since blood concentration does not always reflect true drug effects: cyclosporine
may be at reasonable levels in the blood, but still not be fully exerting its effects at the site of
action 70. Although there is a crude relationship between blood cyclosporine concentrations and
level of T-cell suppression, it is not possible to determine precisely how suppressed T-cell
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function will be based on blood concentrations alone. In human medicine, there is a recognized
need to provide assays that more specifically evaluate the effects of direct suppression of
calcineurin in T cells, especially since calcineurin inhibitors such as cyclosporine tend to have a
narrow therapeutic window 71. In veterinary medicine, this same need is recognized, particularly
when cyclosporine is used to treat either immune-mediated or inflammatory diseases, where
evaluation of the effects of suppression of calcineurin in T cells will most likely better reflect the
effects of cyclosporine on target tissues 31 5.
Pharmacodynamics
The term “pharmacodynamics” refers to the relation between the blood or plasma
concentration of a drug and subsequent effects at the site of action 55. In simple terms,
pharmacodynamic (PD) monitoring evaluates “what the drug does to the body” (or what it does
to target tissues). With cyclosporine, for example, the main focus of PD monitoring would be on
the relationship between the immunosuppressant agent and T-cell responses. While
pharmacokinetic methods of TDM can provide some useful information (high blood
concentrations of cyclosporine, for example, generally correlate with a high level of T-cell
suppression) 72 73, blood concentrations alone cannot accurately predict drug effects. T-cell
suppression and resultant immunosuppression does not depend solely on blood concentration,
but on specific T-cell properties that may vary from individual to individual, such as variability
on lymphocyte P-glycoprotein activity, T-cell cyclophilin levels, calcineurin activity of
lymphocytes, and levels of T-cell production of IL-2 and other NFAT-regulated cytokines 74.
Because they measure actual effects on target tissues, PD assays may be more relevant to clinical
use than PK assays, because they may enable identification of cyclosporine’s specific effect in
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the target T cell, cumulative effects on T cells after multiple doses, and effects on T cells when it
co-administered with other medications 72 73.
The multidrug resistant gene (MDR-1) is the gene coding for the efflux pump Pglycoprotein. The efflux pump is part of the ABC super family, subset B1, and so the gene
responsible for its production is also known as the ABCB1 gene 75. P-glycoprotein is ATPdependent, utilizing ATP derived from hydrolysis. The efflux pump has a unidirectional action,
and functions to remove drugs and toxins from within cells, secreting them into the intercellular
space 76. P-glycoprotein efflux pumps are recognized to occur in cats and dogs, and are found in
multiple different locations, including the blood-brain barrier, the intestines and the liver 29 The
P-glycoprotein pump was first recognized in tumors, where tumors with a better expression of
efflux pump were more resistant to chemotherapeutic agents. An MDR-1 gene mutation has been
recognized in certain dog breeds, where the P-glycoprotein pump does not function properly,
thus allowing higher concentrations of some drugs to accumulate in the blood stream, within
cells, and within organs such as the brain (which is usually protected by the blood-brain barrier),
and this can lead to an increased incidence of drug side effects and intoxication 76. The MDR-1
gene mutation can also lead to increases in the concentrations of cyclosporine within target cells
such as the T cell, thereby increasing the chances of over suppression and drug side effects,
particularly secondary infections 77.
For PD TDM of cyclosporine, while measurement of calcineurin activity is the most
specific measurement available, measurement of calcineurin is a challenging technique.
Calcineurin activity is regulated by intracellular calcium, and peak calcineurin inhibition occurs
in about 1 hour after the oral administration of cyclosporine, with effects persisting for about 4
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hours after administration 78. Trough (more than 6 hours) concentrations of cyclosporine do not
appear to have much effect on calcineurin activity 78.
Since measurement of calcineurin activity is challenging, alternative cyclosporine PD
assays have been developed in human and veterinary medicine. The most commonly used PD in
dogs is now a reverse transcription quantitative polymerase chain reaction (RT-qPCR) technique
previously described (Riggs et al., 2013), which uses the cycle thresholds of activated T cell IL-2
expression to evaluate the cyclosporine-induced suppression of T cell NFAT-associated cytokine
production. Another PD assay that has been used, but that is less feasible for day-to-day TDM,
is a culture-based assay of peripheral blood mononuclear cells (PBMC), where it is possible to
measure IL-2 supernatant with radionuclide DNA tagging and an enzyme-linked immunosorbent
assay 80. Flow cytometry is another analytical method that can be used to assess the effects of
cyclosporine on activated T-cell expression of markers such as IL-2, IL-4, IFN-y, CD25 and
C95, many of which are down-regulated with administration of cyclosporine 5. Flow cytometry,
however, is also not feasible for day-to-day TDM.
Despite the many studies that have been published on the use of cyclosporine in dogs,
there are still many unanswered questions. The Pharmacodynamic Laboratory at MSU has
evaluated samples submitted by veterinarians for the PD assessment of cyclosporine for the past
four years, gathering a large amount of valuable data. We anticipate that a careful analysis of this
accumulated data will provide important information that will serve to greatly increase our
knowledge in this area.
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CHAPTER III
CYCLOSPORINE PHARMACODYNAMIC POPULATIONAL STUDIES IN DOGS
Abstract
Background: Cyclosporine is a xenobiotic isolated from the Tolypocladium inflatum fungus. In
dogs, its main use is to treat immune-mediated and inflammatory diseases. Our laboratory has
developed a pharmacodynamic (PD) assay that measures interleukin-2 (IL-2) produced by
activated T cells as a marker of the immunosuppressive effects of cyclosporine.
Hypothesis/objectives: The objectives of our retrospective study were to extract data from
samples submitted to our laboratory to obtain descriptive statistics, to determine whether assay
results predicted effectiveness of treatment, to determine whether the magnitude of effects was
affected by cyclosporine formulation, and to determine if breed affected PD responses.
Animals: 1,110 samples were analyzed over the 4-year period of the study.
Methods: Data were extracted from submission forms and assay result reports, collated in a
spreadsheet, and analyzed to determine whether there was a relationship between assay results
and control of clinical signs, and whether either cyclosporine formulation or breed affected assay
results.
Results: Data analysis revealed no relationship between assay results and control of signs, and
found that breed did not affect PD assay results. At comparable doses, proprietary modified
cyclosporine had more immunosuppressive effects than proprietary non-modified cyclosporine,
and both proprietary and generic modified formulations had similar efficacy.
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Conclusion: Future prospective studies are indicated that avoid the limitations of a retrospective
study, such as case selection bias and early testing before efficacy can be determined, and that
focus on ascertaining whether cyclosporine dose adjustments based on PD monitoring have a
significant impact on treatment efficacy.
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Introduction
Cyclosporine is a cyclic polypeptide macrolide xenobiotic that has been used as an
immunosuppressive agent in human patients that undergo organ transplantation 1. In veterinary
medicine, cyclosporine is mostly used to treat atopic dermatitis2, immune-mediated diseases such
as immune-mediated hemolytic anemia (IMHA 34), and inflammatory diseases such as
inflammatory bowel disease (IBD) 5. The immunosuppressive effects of cyclosporine, when
given at the dosages recommended for treatment of immune-mediated and inflammatory
diseases, may also predispose to secondary infection 6. In dogs, the most common manifestation
of secondary infection is cutaneous infections, typically observed after prolonged cyclosporine
therapy 6. Inherited variations in cyclosporine metabolic pathways, such as the multidrug
resistance protein 1 (MDR-1; also known as ABCB1) gene mutation affecting the p-glycoprotein
efflux pump, are suspected to predispose some dogs to enhanced drug effects at standard doses,
with a resultant increased risk of infection 7 Another potential concern while using cyclosporine
is that the inhibition of T cells can reduce protective mechanisms for removing abnormal cells,
potentially leading to eventual neoplasia.89
Several formulations of cyclosporine are available to veterinary practitioners: modified
(microemulsified), non-modified, and compounded. Compounding can be performed on either
modified or non-modified cyclosporine, although this is often not clearly specified by the
compounding pharmacy. Additionally, within the category of modified cyclosporine, both
proprietary and generic human and veterinary products are available. Modified cyclosporine is
the drug formulation that is most commonly recommended for oral administration. The utility of
the different cyclosporine formulations at attaining desired effects, however, has not been wellestablished in dogs.
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The Mississippi State University Pharmacodynamic (PD) laboratory has developed a
molecular assay that quantitates RNA coding for interleukin-2 (IL-2) produced by activated Tcells. Cyclosporine is a calcineurin inhibitor that indirectly blocks production of IL-2 by
inhibiting dephosphorylation of nuclear factor of activated T-cells (NFAT). Pharmacodynamic
assays focus on the effects of drugs on the target cells, with dose adjustments based on
measurable drug effects. Our specific PD assay has, for more than 5 years, been offered as a
cyclosporine dosing assessment tool to veterinarians throughout North America and, since then,
over 1,000 samples from dogs receiving cyclosporine therapy have been evaluated. Results of
our PD assay are then used to make dosing adjustment recommendations to veterinarians, with
the goal of targeting a level of T cell suppression that, in human patients, has been established to
provide effective immunosuppression without an excessive risk of secondary infection.
This study was designed to comprehensively extract data from PD testing of samples
submitted to the MSU Pharmacodynamic laboratory. While this was primarily a descriptive
study that extracted, collated, and analyzed all available data, inferential statistical analysis was
focused on three main goals. First, to determine whether the results of our PD assay predicted
prior effectiveness of treatment in individual patients, particularly in terms of reduction of
clinical signs, and in reported suspected side effects such as infection. Second, to determine
whether the magnitude of measurable PD effects was affected by the formulation of cyclosporine
used. Third, to determine if dog breed affected pharmacodynamic responses to cyclosporine,
with a particular emphasis on breeds predisposed to the MDR-1 gene mutation.
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Material and Methods
Sample submission and processing
Blood samples collected from dogs receiving oral cyclosporine for a minimum of one
week were submitted to the PD laboratory by veterinarians throughout North America. The
blood was collected into lithium heparin tubes and placed on ice for overnight delivery. Samples
were typically collected at the time of anticipated peak blood cyclosporine levels (approximately
2 hours after drug administration), but uncommonly blood was collected at the time of
anticipated trough blood levels (approximately 12 hours after drug administration with twice
daily dosing, and 24 hours after administration with once daily dosing). A standardized
submission form (Appendix A) was submitted with each sample, and included information such
as patient signalment (age, breed, weight, and reproductive status), relevant history, current
primary diagnosis or diagnoses, cyclosporine formulation, the dose and dosing frequency of
cyclosporine, duration of therapy, potential side effects, and concurrent medications.
Veterinarians were also specifically asked (Yes/No) if clinical signs of the primary disease had
been controlled at the time of submission.
The PD assay utilized measurement of activated whole blood expression of the RNA
coding for IL-2 by reverse transcription quantitative polymerase chain reaction (RT-qPCR), has
been previously described in detail10. Briefly, upon arrival at our PD laboratory, samples were
divided into two aliquots, activated and unactivated. Activated samples were incubated with
phorbol 12‐myristate 13‐acetate (PMA) (QIAGEN, Germantown, MD) and ionomycin
(QIAGEN, Germantown, MD), and RNA was extracted and stored at -80˚C. IL-2 analysis was
performed in triplicate using a SYBR Green qRT-PCR (QIAGEN, Germantown, MD, USA) on a
Stratagene fast real-time PCR systemd. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
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was used as the housekeeping gene. Stored non-cyclosporine exposed RNA samples from
healthy dogs were concurrently analyzed as normal control samples. The samples were received
weekly, and for each batch of samples, a different control dog was utilized.
Differences in mRNA expression were determined using the difference in delta cycle
threshold of patient sample (ΔΔCtPatSamp) method for the gene of interest (GOI), where
ΔΔCtPatSamp (CtGOI – Ctnorm) post-treatment – (CtGOI – Ctnorm) pre-treatment, with the
relative expression calculated using the formula: (ΔCt - ΔCt ) / ΔCtContDog * 100. Percent
expression was then used to categorize percent T cell suppression into categories established by
our laboratory, with less than 5% of baseline non-suppressed expression considered “marked
suppression”, 5-20% “moderate high suppression”, 20-50% “moderate suppression”, 50-75%
“low suppression”, and 75-100% “no suppression”. Based on interpretation of these results,
recommendations for potential cyclosporine dose adjustments were then made to the
veterinarians that submitted samples for PD analysis.
Data extraction
Complete data were extracted from all sample submission forms and associated PD
laboratory assay results, collected between 2016 and 2020, and collated utilizing a spreadsheet
program. Relevant data extracted from submission forms included patient breed, age, sex, and
neutering status, patient disease and any co-morbidities as listed by the submitting veterinarian,
clinical history, cyclosporine type, dose and manufacturer (including whether drug was nonmodified or modified, proprietary or generic, or compounded), other drug therapy (including
other immunosuppressive agents), potential side effects attributed to cyclosporine use, whether
samples were collected at times of anticipated peak or trough blood levels, and whether the
veterinarian reported clinical signs to be controlled (Yes or No) 11. Relevant data extracted from
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associated PD laboratory assay reports included raw Ct values, ΔΔCt values, percent suppression
of mRNA, and T cell suppression category (Appendix B).
Statistical Methods
Descriptive and inferential statistics were performed using commercially available
statistics software (SAS for Windows v. 9.4, SAS Institute Inc., Cary, NC). The association
between ΔΔCtPatSamp (peak samples only) for all dogs receiving oral cyclosporine twice daily
(any dose and any formulation) and clinical assessment of control of clinical signs (Yes/No) was
assessed using mixed model logistic regression. The same analyses were also performed within
groups of dogs with the three most common diseases (IMHA, IBD/protein-losing enteropathy
[PLE], and immune-mediated thrombocytopenia [ITP]), and within groups of dogs with disease
groups divided into six major categories based on lesion localization (hematologic,
hepatic/gastrointestinal, neurological, skin, muscular and joint disorders), disease groups divided
into two major categories based on diseases where cyclosporine might be expected to exert a
local effect independent of systemic immunosuppression (diseases of the skin, liver and
gastrointestinal tract) and diseases that would be expected to require systemic
immunosuppression in order to respond to therapy, and finally disease groups divided into two
major categories based on diseases where response to therapy is typically expected to be slow
(ie. marrow diseases) and diseases where response to therapy is expected to be faster.
In a linear mixed model, the effect of disease category, hematologic disorders vs hepatic/gastric
disorders, on ΔΔCtPatSamp results in dogs receiving a standard oral dose rate of 4-6 mg/kg
twice daily (modified cyclosporine only), representing a 20% range above and below the median
dose rate of 5 mg/kg twice daily, was assessed. Dogs with cyclosporine formulations (CsAForm)
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listed as “unknown modified” and “unknown” were excluded from the dataset prior to analysis,
due to uncertainty regarding the true form of cyclosporine used.
Additionally, the effect of cyclosporine formulation on ΔΔCtPatSamp results in all dogs
receiving a standard oral dose rate of 4-6 mg/kg twice daily was also assessed in linear mixed
models: select pairwise comparisons between levels of the CsAForm variable were made with
Bonferroni’s adjustment for multiple comparisons. Separate additional models were developed
for each of the CsAForm comparisons previously described (Table A.1). The CsAForm variable
was used to restrict the data to only that needed for each model.
The effect of breed on ΔΔCtPatSamp in dogs on similar standard oral dose rates (4-6 mg/kg
twice daily) of modified cyclosporine was assessed using a linear mixed model. Dog breeds were
categorized for analysis in two ways: firstly, using eight American Kennel Club breed categories
(Foundation Stock Service [FSS], herding, hound, non-sporting, sporting, terrier, toy and
working breds) and, secondly, using breeds with a low frequency of the MDR-1 gene mutation
and breeds with a high frequency of the MDR-1 gene mutation. High frequency of the MDR-1
gene mutation was defined as a prevalence of 50% or greater in the specific breed, as listed by
the Washington State University Clinical Pharmacology Laboratory
(https://vcpl.vetmed.wsu.edu/affected-breeds, accessed 01/13/2021).
In all linear mixed models, delta CT values for control dogs (ΔCtCD) were included as a
covariate. Each week of assayed samples was assigned a batch number, which was also included
as a random variable in all mixed models. Inspection of conditional residuals in all linear mixed
models was used to assess if model assumptions of homoscedasticity and normality of residuals
were met. For all the analyses, an alpha level of 0.05 was used to determine statistical
significance.
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Results
A total of 1,110 samples were analyzed over the four-year period of the retrospective
study. Of these, 845 samples were from dogs receiving cyclosporine twice daily at any dose rate,
and 453 samples were from dogs receiving a roughly similar oral cyclosporine dose of 4-6 mg/kg
twice daily.
Descriptive Statistics:
From all the 1,110 evaluated samples, at any dose range and at any dose frequency,
samples were submitted from 130 different dog breeds. Figure B.1 illustrates the dog breeds
from which more than ten samples were submitted, in order of breed frequency. Dog ages ranged
from less than 1-year-old to 15 years old, with an average patient age of 8 years old and a median
age of 8 (Figure B.2). Dog weights ranged from less than 1 kilogram to 75 kilograms, with an
average patient weight of 17.52 kg and a median weight of 14 kilograms (Figure B.3). Of those
samples where sex was listed on the submission sheet, 30 patients were intact females, 548 were
spayed females, 48 were intact males, and 428 were neutered males (Figure B.4).
A total of 64 different primary diseases were reported. Figure 5 illustrates the reported
diseases with at least ten samples submitted, in order of disease frequency.
The most common frequency of cyclosporine use was twice a day (q12h) at 79.96%,
followed by once a day (q24h) at 19.35% (Figure B.6). Other dosing frequencies were very
uncommonly utilized (less than 1% for any other dosing frequency). For q12h dosing, the mean
dosage was 5.61mg/kg per dose and median dosage was 5 mg/kg, with the range for each
individual dose was 0.5 mg/kg to 30 mg/kg. For q24h dosing, the mean dosage was 6.31mg/kg
and the median dosage was 5.12 mg/kg, and the range for each dose was 1.1 mg/kg to 30 mg/kg.
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Based on all sample submission forms, 798 patients (71.9%) received concurrent
glucocorticoid and cyclosporine (Figure B.7). The most commonly used glucocorticoid was
prednisone with 547 cases (average daily dose rate 1.09 mg/kg), followed by prednisolone with
113 cases (average dose rate 1.22 mg/kg). On 82 submission sheets, clinicians simply reported
“pred”, without specifying whether prednisolone or prednisone was used. Cyclosporine was
uncommonly concurrently administered with other immunosuppressant drugs, with 92 cases
(8.3%) receiving mycophenolate and 29 cases (2.6%) receiving azathioprine (Figure B.8).
From the total of 1,110 sample submission forms submitted, 167 listed a second disease
or condition associated with the main disease (the main reason listed for cyclosporine usage).
Sixteen submission forms (1.5%) listed potential cyclosporine-associated adverse effects,
including gastrointestinal disturbances (vomiting and/or diarrhea; 6 dogs, although one was on
concurrent mycophenolate mofetil and two were on prednisolone), cutaneous papilloma (3 dogs),
urinary tract infection (3 dogs, although 2 were receiving concurrent prednisolone, and the third
was on concurrent mycophenolate mofetil), opportunistic skin infections (2 dogs, both of which
were on concurrent prednisolone), gingival hyperplasia (one dog) and severe leukopenia and
thrombocytopenia (one dog, which was receiving concurrent leflunomide). The categories of T
cell suppression in dogs with potential cyclosporine-associated adverse effects included: 4 dogs
with “no suppression”, 4 dogs with “low suppression”, 5 dogs with “moderate suppression”, and
3 dogs with “moderate high suppression”.
ΔΔCtPatSamp
When all dogs receiving cyclosporine twice daily at any dose rate were evaluated as a
single group, no association was detected between ΔΔCtPatSamp and clinical assessment of
control of clinical signs (Yes/No) (p=.0937) (Figure B.9). To facilitate understanding,
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ΔΔCtPatSamp results in this and subsequent figures have been converted to percent IL-2
expression as previously described, with 0% representing marked suppression of IL-2 expression
and 100% representing no suppression, and presented as box and whiskers plots, with the middle
of the box representing the median, the upper and lower limits of the box representing the 25%
and 75% quartiles, and the whiskers representing the outer ranges. When the same evaluation
was limited only to dogs within the three most common disease groups, no association was
detected between ΔΔCtPatSamp and control of clinical signs for IMHA (p=.3884), IBD/PLE
(p=.9437), and ITP (p=.2459) (Figures B.10 to B.12). Similarly, when diseases were categorized
into six body system categories, no association was detected between ΔΔCtPatSamp and control
of clinical signs for four body systems: hematologic (p=.4219), hepatic/gastrointestinal
(p=.8608), neurological (p=.2794), and joint disorders (p=.6574). For both skin (n=7) and
muscular diseases (n=4), numbers of submitted samples from dogs with twice daily dosing were
too small for statistical analysis. Finally, no association was detected between ΔΔCtPatSamp and
control of clinical signs when diseases were categorized into disorders that might respond to
local drug control (p=.9484) or systemic immunosuppression (p=.1621), and into disorders that
might be slow to respond to therapy (p=.9379 or disorders that might be quick to respond to
therapy (p=.2918).
In all dogs receiving similar oral dose rates (4-6 mg/kg twice daily) of modified
cyclosporine, disease category had a significant effect on ΔΔCtPatSamp results in dogs with
hematologic or hepatic/gastrointestinal disorders (p=0.0075). Dogs with hematologic disorders
had lower ΔΔCtPatSamp results compared to dogs with hepatic/gastrointestinal disorders (Figure
B.13).
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Evaluation of the effect of cyclosporine formulation (CsAForm) on ΔΔCtPatSamp results
in dogs on similar oral dose rates (4-6 mg/kg twice daily) (Table A.1) did not detect significant
differences between formulations (p=.1980) when making all comparisons listed in Table A.1
within one model. In separate models for each comparison, there was a significant (p=.0310)
difference in the ΔΔCtPatSamp results between proprietary modified cyclosporine (Atopica or
Neoral) and proprietary non-modified cyclosporine (Sandimune) (Figure B.14). There was no
difference detected (p=0.5255) between proprietary modified and generic modified cyclosporine
formulations compared to compounded modified formulations. For the two most common
cyclosporine formulation categories, proprietary modified (n=276) and generic modified (n=82),
there were no significant differences detected among the ΔΔCtPatSamp results. (Figure B.15)
The effect of breed on ΔΔCtPatSamp in dogs on similar oral dose rates (4-6 mg/kg twice
daily) of modified cyclosporine revealed no significant (p=.1099) differences between
ΔΔCtPatSamp results in the various AKC categories of Foundation Stock Service (FSS). (Figure
B.16). Additionally, in dogs on the same oral dose rate, no significant (p=.6122) differences in
ΔΔCtPatSamp results were detected between dogs categorized into non-MDR1 and MDR1
breeds (Figure B.17).

36

Discussion
Our study determined that there was no relationship between PD assay results and
clinician-reported control of clinical signs, and the study results did not support the hypothesis
that adequacy of T-cell suppression predicted response to therapy. The original purpose of the
PD assay, however, was to direct potential cyclosporine dose adjustment, and clinicians were
therefore encouraged to submit samples within several weeks of commencing therapy. For many
patients, therefore, even if they were receiving the correct cyclosporine dose to effectively treat
their specific condition, samples may have been submitted too soon for attending veterinarians to
observe clinical remission. In fact, of the samples subjected to this analysis where the submitting
veterinarian listed commencement date, nearly half were submitted in the first month of therapy:
20.6% within the first 2 weeks of commencing therapy, a further 22.7% within 2-4 weeks of
commencing therapy, and the remainder (56.7%) after at least 4 weeks of therapy.
Our study did not detect a relationship between PD assay results and control of clinical
signs within individual disease categories. Additionally, a relationship was not detected between
the PD assay results and disorders expected to respond slowly compared to diseases that might
respond more rapidly and disorders that cyclosporine would be expected to have a local versus
system effect. A recent large population pharmacokinetic study based on measurement of blood
cyclosporine concentrations (rather than on a pharmacodynamic assay) did not detect a
correlation between blood drug concentration and veterinarian-reported control of clinical
signs12. This population pharmacokinetic study, however, presumably had the same limitation as
our study, in that samples were most likely submitted primarily to facilitate dose adjustments if
needed and may therefore have often been evaluated relatively early in the treatment course.
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Much of the cyclosporine that is absorbed through the gastrointestinal tract is eventually
secreted back into the intestinal lumen by the hepatobiliary system. Resultant enterohepatic
circulation creates the potential for higher drug concentrations in the gastrointestinal tract and
liver than might be encountered in the systemic circulation. Cyclosporine has also been shown to
be concentrated and persist in the dermis13. For these reasons, blood drug concentrations and
systemic pharmacodynamic effects, such as the effect of cyclosporine on T-cell cytokine
production that was measured by our assay, may not accurately reflect actual drug effects at the
level of the gastrointestinal tract, liver, and skin. In fact, for the treatment of conditions such as
atopy and IBD, blood cyclosporine concentrations have been demonstrated to not correlate with
treatment efficacy14 15. For this reason, as well as considering all treated dogs as a single group,
regardless of disease, we also separately analyzed the ability of the results of our
pharmacodynamic assay to predict control of clinical signs for dogs with conditions that affected
the gastrointestinal tract, liver and skin, and with conditions that would be more likely to require
systemic immunosuppression, but found no differences between disease groups.
In dogs on comparable oral dosages of modified cyclosporine (4-6 mg/kg q12h), we
detected no significant difference between the degree of suppression of IL-2 production and the
type of cyclosporine formulation. In contrast, compared to the proprietary non-modified
cyclosporine, dogs receiving proprietary modified cyclosporine had a higher level of
suppression. Many different formulations of cyclosporine were submitted to the PD lab,
including proprietary (both human and veterinary brand name) modified, generic (both human
and veterinary, from multiple different manufacturers) modified, proprietary non-modified,
generic non-modified, compounded modified, and compounded non-modified. In many
instances, particularly with generic and compounded cyclosporine, it was not possible to
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determine from the submission sheet whether the cyclosporine was modified or non-modified. In
our experience, many veterinary compounding pharmacies do not provide readily available
information to veterinarians regarding whether their product is modified or non-modified.
“Modified” cyclosporine is micro-emulsified or ultra-micronized cyclosporine, where the active
substance is stabilized in an emulsion of water, oil and surfactants, a process designed to
increase drug bioavailability, and to also make bioavailability more predictable 16 17. For this
reason, in both human and veterinary medicine, modified cyclosporine has for several decades
been recommended as the preferred cyclosporine formulation. Additionally, proprietary modified
cyclosporine is often recommended in preference to generic modified cyclosporine.
Our study confirmed that, in dogs receiving oral proprietary cyclosporine at comparable
doses, there was a difference in pharmacodynamic assay results between modified (Neoral®,
Atopica®) and non-modified (Sandimmune®) formulations, with greater suppression with
modified cyclosporine (median suppression 15% greater with the modified product), providing
support for previous recommendations that the modified product is the optimal formulation for
use in dogs. This difference was sufficient to be detectable, even considering that only a very
limited number of patients (5 dogs) were prescribed proprietary non-modified cyclosporine. In
contrast, our study revealed no significant difference between the pharmacodynamic effects of
the proprietary modified cyclosporine and the generic modified cyclosporine, the two
formulations most commonly used for samples submitted to our laboratory. Generic modified
cyclosporine is typically less expensive than proprietary cyclosporine, and the results of our
study suggest that clinicians can consider using generic rather that proprietary modified
cyclosporine, without an appreciable diminishment of immunosuppressive effects. While there is
now a veterinary generic modified cyclosporine (Cyclavance®), only human generic modified
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cyclosporine was available at the time that the majority of samples submitted to our laboratory,
and our findings may not necessarily be extrapolatable to the new veterinary product. While,
with the exception of proprietary modified cyclosporine versus proprietary non-modified
cyclosporine, there was no statistical difference between the pharmacodynamic effects of any of
the cyclosporine formulations evaluated at comparable dose rates, for the less commonly used
formulations such as compounded cyclosporine, sample sizes were small, and were therefore
most likely underpowered for detecting significant differences.
Our study revealed that dog breed had no effect on the pharmacodynamic effects of
cyclosporine in dogs on comparable oral dose rates. While, with well over 100 breeds
represented, no individual dog breed was present in large enough numbers to feasibly allow
comparison between individual breeds, no significant difference was detected between AKC
breed groups, nor between breeds with a low and a high incidence of the MDR-1 gene mutation.
The median weight of treated dogs was in the 10 to 15 kg range, and the predominance of
relatively small dogs in this study may be due to the high cost of cyclosporine compared to many
other immunosuppressive agents, potentially making the drug prohibitively expensive for owners
of some larger dogs. Additionally, the availability of veterinary-approved cyclosporine in
multiple different capsule sizes and liquids designed for smaller patient sizes undoubtedly
facilitated the dosing of smaller dogs.
The multidrug resistant gene (MDR-1), also known as the ATP binding cassette B1 gene
(ABCB1), is the gene coding for the efflux pump P-glycoprotein. P-glycoprotein efflux pumps
are found in multiple different organs and tissues, including the blood-brain barrier, intestines,
liver, and T-cell surface membrane 18. Efflux pumps appear to play an essential role in removing
cyclosporine from the T-cell cytoplasm. In patients with an MDR-1 gene mutation affecting P40

glycoprotein function, the concentration of cyclosporine inside the T cell would be anticipated to
be higher than concentrations achieved in patients without the gene mutation. MDR-1 gene
mutations have been recognized to occur at high frequencies in certain dog breeds, and can
predispose to an increased incidence of drug side effects and intoxication 19. In dogs receiving
cyclosporine, the MDR-1 gene mutation may predispose to excessive immunosuppression at
standard drug doses, with resultant secondary infections 7. Dog breeds with an over 50% chance
of MDR-1 gene mutations are the Australian shepherd (50%), miniature Australian shepherd
(50%), collie (70%) and the long-haired whippet (50%)(K. Mealey, et. al 2016). In our study,
MDR-1 gene mutation predisposed breeds were not unequivocally demonstrated to be
susceptible to enhanced T cell suppression at standard oral doses although, since submitting
veterinarians did not routinely perform or report MDR-1 genetic testing, it is not possible to
know what proportion of dogs in our study had the gene mutation. Interestingly, breeds at risk
for the MDR-1 gene mutation had an approximately 15% lower median expression of IL-2, at the
same oral dose rate range, than breeds not at risk, although this difference did not achieve
statistical significance. Since only 15 samples were submitted from dogs at risk for the MDR-1
gene mutation within the evaluated dose range, it is likely that our study was underpowered to
detect differences between breeds that are susceptible to the gene mutation and breeds that are
not. Further studies of the effects of the MDR-1 gene mutation on cyclosporine
pharmacodynamics in dogs are warranted, with a particular focus on dogs that are known to have
the mutation based on genetic testing.
A second factor that has the potential to alter patient responses to cyclosporine is the
level of individual patient cytochrome P450 (CYP) enzyme activity. CYP enzymes can be found
in the endoplasmic reticulum of cells within the liver, intestines, brain, and other organs, and are
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responsible for drug metabolization, generating both active and inactive metabolites. CYP
enzymes are divided into several subfamilies, and these sub-families are recognized to
metabolize different groups of drugs 21. Cyclosporine is a substrate for CYP enzyme
metabolization, and in humans the main sub-family that metabolizes cyclosporine is 3A5, with
minor metabolization by 3A4, 3A7 and 3A43 22. In dogs, the CYP sub-family that metabolizes
cyclosporine is not fully defined although, based on the known inhibition of cyclosporine
metabolism by ketoconazole, the CYP enzyme 3A12 is suspected to play an important role.
Inherited variability in CYP enzyme activity and acquired variations in CYP activity induced by
exposure to other drugs both have the potential to affect patient responses to cyclosporine. One
additional factor that can affect the immunosuppressive effects of cyclosporine is the T cell
cytoplasmic concentration of cyclophilin A. Cyclophilin A binds to intracellular cyclosporine
and enhances drug-associated inhibition of calcineurin. Cyclophilin A is therefore essential for
the cyclosporine to exert its immunosuppressive effects on T cells 23. In fact, one study in mice
revealed that a gene mutation affecting peptidyl-propyl isomerase A (PPIA), one of the proteins
that forms cyclophilin A, can lead to a marked a resistance towards the immunosuppressive
effects of cyclosporine 24. Our study explored the effects of different breed groups on patient
responses to cyclosporine in an attempt to identify particular breed predilections to enhanced or
decreased drug effects, with the aim of potentially of then identifying specific genetically defined
factors that affected cyclosporine responsiveness, but no particular breed associations were
recognized.
For evaluation of the effects of cyclosporine formulation and breed on pharmacodynamic
assay results, we selected only those dogs receiving comparable drug doses. A cyclosporine dose
range of 4 to 6 mg/kg was selected based on recommended standard immunosuppressive dose of
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cyclosporine of 5 mg/kg twice daily for treatment of conditions such as IMHA 25 and on the
commonest twice daily doses used from data analysis of all of the samples submitted to our
laboratory (mean 5.61 mg/kg, median of 5 mg/kg). A final dose range of 4-6 mg/kg represented a
range 20% above and 20% below a median dose of 5 mg/kg. For the breed analysis, we also
chose to only include dogs on proprietary modified and generic modified cyclosporine, because
of the more predictable bioavailability of the modified formulations.
Remarkably few potential cyclosporine-associated adverse effects (1.5%) were reported
by veterinarians but, since the submission sheets used did not specifically request that clinicians
report drug side effects, it is likely that side effects were under-reported. In addition, because
dogs were often receiving multiple immunosuppressive drugs, it was often not possible to
distinguish the effect of the cyclosporine from the potential effects of concurrent drugs such as
prednisolone (urinary tract infections, and opportunistic skin infections), mycophenolate mofetil
(gastrointestinal disturbances), or leflunomide (possible myelosuppression). A number of
adverse effects, such as cutaneous papilloma, gastrointestinal disturbances, and gingival
hyperplasia, were uncommonly observed in dogs receiving cyclosporine monotherapy, and all of
these suspected adverse effects have been previously associated with cyclosporine therapy 8.
Interestingly, although patient numbers were too low for statistical analysis, suspected adverse
effects did not appear to be related to pharmacodynamic detection of marked T cell suppression.
Our study also evaluated the effects of disease and disease category on pharmacodynamic
assay results in dogs receiving comparable oral dose rates of modified cyclosporine. For the
majority of diseases and disease categories, disease had no impact on the degree of cyclosporinemediated suppression of IL-2 expression. However, at comparable cyclosporine dose rates,
suppression of IL-2 expression was greater in dogs with IMHA (approximately 15% decrease in
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IL-2 expression) than it was in dogs with gastrointestinal/hepatic disease. Since the majority of
dogs in gastrointestinal/hepatic disease group had gastrointestinal diseases such as IBD and PLE,
we hypothesize that this effect is due to decreased intestinal cyclosporine absorption, and
therefore reduced oral bioavailablity, in dogs with significant gastrointestinal disease. The
impact of gastrointestinal disease on cyclosporine bioavailability has not been thoroughly
evaluated in either humans or dogs although, interestingly, while in one study in people
concurrent gastrointestinal disease had no significant effect on cyclosporine blood levels with
chronic oral therapy, blood drug levels were actually transiently comparatively increased after
the first oral dose in human patients with gastrointestinal disease 26.
Our study had several limitations common to many retrospective studies. Firstly, patient
submission sheets were primarily designed to provide the information needed to allow for dose
adjustment recommendations, and not for retrospective data analysis. Our original data
submission forms only asked submitting veterinarians if clinical signs were controlled or not, and
not whether the disease was in complete remission or not, which rendered it impossible to
retrospectively distinguish dogs in true clinical remission from asymptomatic dogs that were not
yet in remission (dogs with subclinical anemia, for example). Additionally, many veterinarians
provided incomplete data or, when information was provided, handwritten submissions were not
always legible. Furthermore, recommended timings of sample submission were designed
primarily for dose adjustments, at one to two weeks after commencing drug therapy, rather than
the one or two months post-treatment that would be needed to optimally assess clinical response
to therapy. From all of the samples submitted from dogs on twice daily dosing, only 53%
(n=410) were reported to have clinical signs controlled, while 43% (n=334) were reported to be
not clinically controlled. Such a relatively high proportion of poorly controlled signs may be
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consistent with an early use of the assay for initial dose adjustment. Alternatively, this may
reflect practitioner case selection bias, in that clinicians are probably more likely to submit
samples from patients in which disease is not yet controlled . Finally, many dogs were on
multiple drugs with immunosuppressive effects, and the effects of cyclosporine on T cell
function could therefore not be distinguished with absolute certainty from the effects of other
drugs. Although other commonly used immunosuppressive drugs such as mycophenolate and
azathioprine appear to have minimal effects on T-cell NFAT-associated cytokine production,
immunosuppressive doses of glucocorticoids have been shown to have mild to moderate effects
on activated T-cell expression of cytokines such as IL-2, and many of the dogs in our study were
receiving concurrent glucocorticoids such as prednisone and prednisolone. 27
In summary, our extensive retrospective population pharmacodynamic study revealed
that non-modified cyclosporine and modified cyclosporine at the same dose rate had appreciably
different pharmacodynamic effects, and that there was no appreciable difference between the
immunosuppressive effects of proprietary and generic modified cyclosporine formulations. Our
study did not detect any breed-related differences in responsiveness to cyclosporine and failed to
confirm that an assay based on activated T-cell expression of IL-2 predicted response to
cyclosporine therapy. Future prospective studies are indicated that avoid the significant
limitations of a retrospective study, and that focus on ascertaining whether cyclosporine dose
adjustments based on pharmacodynamic monitoring have a significant impact on treatment
efficacy.
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CHAPTER IV
CONCLUSION
The Pharmacodynamic Laboratory at Mississippi State University developed four main
questions to be addressed by our retrospective study:
1. Does our pharmacodynamic assay predict clinical response to treatment?
2. Are there specific breed-associated genetic mutations that alter metabolism of
cyclosporine or response to therapy?
3. Does disease process affect pharmacodynamic responses in dogs?
4. Do different cyclosporine formulations affect pharmacodynamic responses?
In our study, we found that the results of our assay were not associated with clinical
control of disease. It is possible that this lack of association was at least in part due to timing of
sample submission. Samples were often submitted in the first few weeks of treatment, when
veterinarians were seeking initial dose adjustment recommendations. However, since it is likely
that some patients had diseases that took longer than a few weeks to respond to therapy, there
might not have be enough time to enable adequate assessment of response to therapy.
Additionally, because of the retrospective nature of the study, with the associated lack of control
over clinician decision making, for many cases we do not receive a follow up sample to fully
assess if the dose adjustment was effective or not. Ideally the samples should have been
submitted before the start of cyclosporine therapy, and then at least one week after the start of
treatment, and then again at least one week after any dose adjustment. This approach would
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allow us to know the basal levels of activated T cell IL-2 expression, to determine if the initial
dose attained target immunosuppression, and, if not, whether subsequent dose adjustments
successfully met recommended targets. Collection of this type of comprehensive information
would, however, be very difficult to coordinate with veterinarians.
In our study, we could not find any significant statistical relationship between breeds,
including breeds predisposed to the MDR-1 gene mutation, and degree of immunosuppression at
the same dose rate,the number of dogs in breeds predisposed to the MDR-1 gene mutation
sample was small (n=15) compared to non-MDR-1 gene mutated samples (n=444), which
reduced the power of our study to detect differences between groups. However, the few samples
we had that were MDR-1 gene mutated according to Washington state University list did show
more suppression compared to non-MDR-1 gene mutated dogs, what may indicate that they are
more sensible to the effects of cyclosporine. It would be interesting to study even further this
comparison with a bigger population. Based on our understanding of cyclosporine metabolism,
we can assume that mutations on the MDR-1 gene will lead to reduced lymphocyte Pglycoprotein efflux pump activity, which would lead to increased drug concentrations inside Tcells, potentially leading to enhanced drug effects on the cell. Categorization of breeds using the
American Kennel Club categories (Foundation Stock Service), herding, hound, non-sporting,
sport, terrier, toy and working breeds) allowed us to further evaluate for differences in
suppression at similar doses between larger breed groups. However, with this breed group
analysis, there was no difference between groups. Our study therefore failed to detect any
significant breed-related and presumably inherited effects on drug metabolism and efficacy.
Our study evaluated the effects of different diseases on degree of T cell suppression in
dogs on comparable doses of cyclosporine, and determined that a difference in responses in dogs
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with immune-mediated hemolytic anemia (IMHA) compared to dogs with inflammatory bowel
disease (IBD). We hypothesize that the treated disease could actually have an impact on
cyclosporine’s pharmacodynamic effects. For example, it is possible that patients with IMHA,
which is a systemic inflammatory disease that has the potential to ramp up immune system
responses, may not respond to the immunosuppressive effects of cyclosporine as completely as
patients with other diseases. It is also possible that, in patients with IBD, the may cause an
increase of permeability and a breakdown of barriers to drug absorption in the GI tract, allowing
cyclosporine to enter the system more easily than in dogs with non-gastrointestinal diseases.
Interestingly, all of the modified formulations of cyclosporine (proprietary and generic)
caused similar suppression of T-cell function in patients receiving cyclosporine at comparable
dose rates. We can recommend, based in our results, the use of generic modified cyclosporine,
which appears to have similar immunosuppressive efficacy to proprietary modified cyclosporine,
when cost is a concern to the patient’s owners. Since the vast majority of patients received
proprietary or generic modified cyclosporine, for most other comparisons (modified versus nonmodified, compounded versus non-compounded) sample sizes were so small that the study was
underpowered to detect statistical significance . However, even with relatively small sample
sizes, it was noticeable that, at comparable dose rates, the degree of suppression of IL-2 was less
in the few patients receiving non-modified cyclosporine than it was in the patients receiving
modified cyclosporine. We assume that this effect occurred because of the well-established
reduced bioavailability of non-modified cyclosporine compared to micro-emulsified “modified”
cyclosporine, leading to likely lower blood drug concentrations, and subsequent less
immunosuppressive effects, in dogs receiving the non-modified formulation.
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During our research, we recognized a number of limitations. One of these was related to
the submission form, where there was a considerable degree of variation in how veterinarians
submitting samples reported information. One example of this issue was with the question where
we asked if the patient’s clinical signs were controlled or not. Based on non-clinical parameters
such as bloodwork, it was possible for the patient to not be expressing clinical signs, but to still
not be in complete remission. Room for variations in reporting has subsequently been reduced in
our new submission form where we ask two questions: are clinical signs controlled or not, and is
it the patient in remission or not? The need to collect extra, more detailed, and more accurate
information must, however, be balanced with the need to keep forms simple enough that they
don’t dissuade the veterinarians from completely adding all requested information. Another
common issue that we encountered was that the quality of the information that we collected was
highly dependent on factors that were influenced by the submitting clinician: for example,
samples were submitted at times and in conditions that were not recommended by our laboratory,
some samples were in incorrect tubes or had clots in them, some samples were of such limited
volume that accurate testing could not be guaranteed, and many submission forms had
incomplete information on important information such as cyclosporine dosage, formulation or
total time of treatment. This issue made hard for our clinicians to give a complete feedback to
veterinarians on dosage adjustment, and also reduced the quality of information collected in our
study.
A possible idea for future studies, and an approach that may allow us to better understand
if our assay does or not help patients attain disease control, is to select certain samples for
common diseases such as IMHA and ITP that were submitted in the past year, and to then call
the veterinarians that submitted the samples and determine on how the patients are now doing,
52

with or without dose adjustments recommended by our laboratory. This may give us a better
understanding on how dose adjustments of cyclosporine based on our assay are actually affecting
progress of these cases.
From this point on, we need to consider moving our focus to another areas, for instance,
do genetic mutations such as the MDR-1 gene mutation truly affect the metabolism and
effectiveness of cyclosporine, and are there other genetic mutations that would influence
cyclosporine metabolism and efficacy? For example, we could investigate mutations related to
the gene that determines intracellular cyclophilin. We could also more aggressively seek baseline
samples from patients that have not yet started cyclosporine treatment, to determine if knowing
basal levels of IL-2 expression would increase the accuracy of recommendations for dosage
adjustment to clinicians. This may make our assay recommendations more accurate when
suggesting dose adjustments. Additionally, we could explore the use of our assay with dogs
receiving tacrolimus, another calcineurin inhibitor, and compare the level of T cell suppression
between cyclosporine and tacrolimus, thereby determining which agent may be preferable for
specific diseases, and potentially identifying a lower dose of tacrolimus in dogs that may cause T
cell suppression without the risk of intussusception. Our assay is having been widely used in
dogs receiving cyclosporine for the past 7 years, and it would likely also provide beneficial
information in cats receiving the same drug, if a practical assay could be developed in this
species.
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TABLES
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Table A.1

Drugs affecting either CYPs (C) and P-glycoproteins (P), leading to decreased
cyclosporine concentrations. 21 32 34

Decreased Cyclosporine Concentration
Azathioprinec

Carbamazepinec

Clindamycinc

Cyclophosphami
dec
Phenobarbitalc,p

Famotidinec,p

Griseofulvinc

Octreotidec,p

Rifampinc,p

Sulfadiazinec

Sulfamethoxazolec Sulfasalazinec

Trimethoprimc

Warfarinc

List of drugs that will decrease the bioavailability of cyclosporine.
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Dexamethasonec,
p

Phenytoinc
Terbinafinec

Table A.2

Drugs affecting either CYPs and P-glycoproteins, leading to increased
cyclosporine concentrations. 21 32 34

Increased Cyclosporine Concentration
Acetazolamide

Allopurinolc

Amlodipinec

Amiodaronec

Azithromycinp

Bromocriptinep

Carvedilolp

Chloramphenicolc,p

Clarithomycinc,p

Clopidogrelc.p

Cimetidinec.p

Ciprofloxacinc

Cisapridec

Colchinec,p

Danazolc

Digoxinp

Diltiazenc

Erythromycinc,p

Estrogensc

Fluvoxaminec

Fluconazolec,p

Itraconazolec

Imatinibc

Imipenemc,p

Ketoconazolec,p

Grapefruit
Juicec
Losartanc,p

Methylprednisolonec

Metoclopramidec

Metronidazolec

Midazolamc,p

Nefazodonec

Omeprazolec

Prednisonec

Prednisolonec

Quinuspristinp

Sertralinec

Tinidazolec

Verapamilc

Vitamin Ec

List of drugs that will increase or contribute the bioavailability of cyclosporine
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Table A.3

Comparisons made between all the cyclosporine formulations

Comparison 1

Proprietary Modified

Generic Modified

Comparison 2

Proprietary Modified

Compounded Modified

Comparison 3

Generic Modified

Compounded Modified

Comparison 4

Proprietary Modified

Compounded Unknown

Comparison 5

Proprietary Modified

Proprietary Non-Modified

Comparison 6

Compounded Modified

Comparison 8

Proprietary Modified +
Generic Modified
Proprietary Modified +
Generic Modified
Proprietary Modified

Comparison 9

Generic Modified

Comparison 7

Comparison 10

Proprietary Modified +
Generic Modified
All comparisons made between cyclosporine formulations.

57

Compounded Unknown
Compounded Modified +
Compounded Unknown
Compounded Modified +
Compounded Unknow
Compounded Modified +
Compounded Unknown

APPENDIX B
FIGURES
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Figure B.1

Number of samples submitted, separated by dog breed, with 10 breeds or more
represented.
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Figure B.2

Number of samples submitted, by age.
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Figure B.3

Number of samples submitted, by weight of dog in kilos.
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Figure B.4

Percentage of samples submitted, by sex of dogs. (F – Intact female, FS – Female
spayed, M – Intact male, MN – Male neutered
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Figure B.5

Disease frequency amongst samples submitted, for samples with more than 10
cases of the disease listed by the submitting veterinarians.

(IMHA – immune-mediated hemolytic anemia, IBD – inflammatory bowel disease, ITP –
immune-mediated thrombocytopenia, IMPA – immune-mediated polyarthritis, PLE – protein
losing enteropathy, CUPS – chronic ulcerative periodontal stomatitis, PRCA – pure red cell
aplasia, GME – granulomatous meningoencephalitis, IMN - immune-mediated neutropenia).
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Figure B.6

Percentage of samples submitted, separated by dose frequency.

(q24h – once daily, q12h – twice daily, q8h – three times daily, EOD – every other day, E2D –
every two days, E3D – every three days).

64

Figure B.7

Frequency of steroids used in association with cyclosporine, all doses and dosing
frequencies (n =796).
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Figure B.8

Frequency of immunosuppressive medications used in association with
cyclosporine, all doses and dosing frequencies (n = 140).
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Figure B.9

Control of clinical signs (Yes/No) in relation to pharmacodynamic assay results,
dogs receiving an oral modified cyclosporine, all doses, twice a day, all diseases
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Figure B.10 Control of clinical signs (Yes/No) in relation to pharmacodynamic assay results,
dogs receiving an oral modified cyclosporine, all doses, twice a day, dogs with
IMHA.
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Figure B.11 Control of clinical signs (Yes/No) in relation to pharmacodynamic assay results,
dogs receiving an oral modified cyclosporine, all doses, twice a day, dogs with
IBD and/or PLE.
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Figure B.12 Control of clinical signs (Yes/No) in relation to pharmacodynamic assay results,
dogs receiving an oral modified cyclosporine, all doses, twice a day, dogs with ITP
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Figure B.13 Comparison of IL-2 expression between dogs with hematological and
hepatic/gastrointestinal disease, in dogs receiving oral modified cyclosporine
within a dose range of 4-6mg/kg, twice a day
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Figure B.14 Comparison of IL-2 expression on samples using proprietary modified
cyclosporine versus proprietary non-modified cyclosporine (Sandimmune®),
within an oral cyclosporine dose range of 4-6mg/kg, twice a day.
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Figure B.15 Comparison of IL-2 expression in samples using proprietary modified cyclosporine
versus generic modified cyclosporine, within an oral modified cyclosporine dose
range of 4-6mg/kg, twice a day
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Figure B.16 Comparison of IL-2 expression on samples, separated by the American Kennel
Club classification of breeds, within an oral modified cyclosporine dose range of
4-6mg/kg, twice a day

.
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Figure B.17 Comparison of IL-2 expression on samples separated by MDR-1 gene mutation at
risk dog breed (classification found at https://vcpl.vetmed.wsu.edu/affected-breeds,
accessed on 12/12/2021) and non MDR-1 gene mutation breeds, within an oral
modified cyclosporine dose range of 4-6mg/kg, twice a day.
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